Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768017 | 0.91 | STS (0.52) | STSPTPRBPTPN11NAMPTMAPT | |
| SCHEMBL4770596 | 0.81 | PTPRB (0.44) | STSPTPRBPTPN11LMNAMAPT | |
| SCHEMBL5567930 | 0.79 | STS (0.44) | STSP2RX7PTPRBPTPN11LMNA | |
| SCHEMBL4776450 | 0.78 | STAT3 (0.44) | LMNAMAPT | |
| SCHEMBL5568808 | 0.78 | STS (0.54) | STSBRD4LMNAMAPT | |
| SCHEMBL5571647 | 0.76 | MAPK14 (0.47) | LMNA | |
| SCHEMBL5572114 | 0.75 | IL1B (0.38) | STSP2RX7LMNATGFBR1 | |
| SCHEMBL28358887 | 0.74 | NAMPT (0.45) | NAMPTBRD4USP30JAK2JAK1 | |
| SCHEMBL6917648 | 0.73 | NAMPT (0.52) | NAMPTMAPTUSP30JAK2JAK1 | |
| SCHEMBL12279408 | 0.73 | MEN1 (0.57) | STSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | STS 4478/4885P2RX7 4514/4885PTPRB 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.